Yao Rui-Jie, Wang Mao-Yuan, Chen Qiang, Xiao Hong, Yang Peng, Ding Yi-Lang, Chen Xi, Tang Song-Xi, Zhou Hui-Liang
Department of Andrology and Sexual Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
Sex Med. 2024 Sep 29;12(4):qfae065. doi: 10.1093/sexmed/qfae065. eCollection 2024 Aug.
Low-intensity extracorporeal shock wave therapy (Li-ESWT) is a new method for treating erectile dysfunction (ED), but there are no standards yet for its indications.
The study aimed to suggest the early clinical efficacy of Li-ESWT and explore its related factors in young and middle-aged patients with ED who responded to phosphodiesterase type 5 Inhibitors (PDE5Is).
Data from 61 patients with ED who had previously responded to oral PDE5Is and subsequently underwent Li-ESWT were collected. This included information on age, body mass index, total testicular volume, sex hormones, as well as IIEF-EF scores before treatment and at 1, 3, and 6 months after treatment. The treatment regimen involves a weekly session for four consecutive weeks, with each session administering 5000 shock wave pulses. Linear regression analysis was utilized to identify factors associated with the efficacy of Li-ESWT treatment. Additionally, the improvement in different severity groups of ED before and after treatment, along with their IIEF-EF scores, was compared.
Li-ESWT was more targeted and effective for young and middle-aged patients with erectile dysfunction who responded to PDE5Is.
The age of enrolled patients ranges from 22 to 53 years old, and the IIEF-EF scores at 1 month, 3 months, and 6 months after treatment were compared to baseline for efficacy assessment, showing significant improvements ( < .0001) in all instances. Linear regression analysis using baseline data revealed predictive factors associated with treatment efficacy: treatment efficacy was negatively correlated with baseline IIEF-EF scores ( = -2.599, = .013) and positively correlated with baseline LH levels ( = 2.170, = .036).
Given the considerable cost of Li-ESWT treatment and the emphasis on treatment continuity, we hope to identify the most suitable candidates for Li-ESWT therapy, thereby optimizing its application.
Our findings provide a better solution for nonelderly ED patients who are responsive to PDE5Is. This study was limited by our sample size and follow-up time.
After 3 months of Li-ESWT, the IIEF-EF score gradually stabilizes and short-term maintenance of PDE5Is medication increases the responsiveness to shock wave therapy.
低强度体外冲击波疗法(Li-ESWT)是治疗勃起功能障碍(ED)的一种新方法,但目前其适应症尚无标准。
本研究旨在探讨Li-ESWT对口服5型磷酸二酯酶抑制剂(PDE5Is)有效的中青年ED患者的早期临床疗效,并探索其相关因素。
收集61例既往对口服PDE5Is有反应且随后接受Li-ESWT治疗的ED患者的数据。这包括年龄、体重指数、总睾丸体积、性激素信息,以及治疗前和治疗后1、3、6个月的国际勃起功能指数-勃起功能(IIEF-EF)评分。治疗方案为连续四周每周治疗一次,每次治疗给予5000次冲击波脉冲。采用线性回归分析确定与Li-ESWT治疗疗效相关的因素。此外,比较了治疗前后不同严重程度ED组的改善情况及其IIEF-EF评分。
Li-ESWT对口服PDE5Is有反应的中青年勃起功能障碍患者更具针对性且有效。
入组患者年龄在22至53岁之间,将治疗后1个月、3个月和6个月的IIEF-EF评分与基线进行比较以评估疗效,所有情况下均显示出显著改善(<0.0001)。使用基线数据进行的线性回归分析揭示了与治疗疗效相关的预测因素:治疗疗效与基线IIEF-EF评分呈负相关(=-2.599,=0.013),与基线促黄体生成素(LH)水平呈正相关(=2.170,=0.036)。
鉴于Li-ESWT治疗成本较高且强调治疗的连续性,我们希望确定最适合Li-ESWT治疗的患者,从而优化其应用。
我们的研究结果为对PDE5Is有反应的非老年ED患者提供了更好的解决方案。本研究受样本量和随访时间的限制。
Li-ESWT治疗3个月后,IIEF-EF评分逐渐稳定,短期维持PDE5Is药物治疗可提高对冲击波治疗的反应性。